Vaccinex, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.vaccinex.com

Safety Score

Market Cap $2.07M
Debt $44.00K
Cash $2.91M
EV -$793.09K
FCF -$15.87M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$18.58M
EBIT	-$18.58M
ROA	-383%
FCF	-$15.87M
Equity	-$1.32M
Growth Stability	1
PE	-0.11
PB	-1.57
P/FCF	-0.13
P/S	5.33
Price/Cash	1.4
Debt/Equity	-0.03
Debt/FCF	-0
Net Margins	-4K%
Op. Margins	-5K%
Sales Growth YoY	160%
Sales Growth QoQ	-78%
Sales CAGR	-2%
Equity CAGR	-3%
Earnings Growth YoY	17%

Earnings Growth QoQ	2%
Sales CAGR 5Y	9%
Equity CAGR 5Y	-6%
Earnings CAGR 3Y	1%
Sales CAGR 3Y	1%
Equity CAGR 3Y	-12%
Market Cap	$2.07M
Revenue	$388.00K
Assets	$4.85M
Total Debt	$44.00K
Cash	$2.91M
Shares Outstanding	1.72M
EV	-793.09K
Safety Score	32%
Working Capital	-1.42M
Current Ratio	0.77
Shares Growth 3y	32%
Equity Growth QoQ	-54%
Equity Growth YoY	-66%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's product pipeline includes pepinemab (VX15), which targets Huntington's Disease (HD) and non-small cell lung cancer (NSCLC) and also neurodegenerative disorders; VX5 Autoimmune for the treatment of MS and potentially for other autoimmune disorder; and others.

SEC Filings

Direct access to Vaccinex, Inc. (VCNX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Vaccinex, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Vaccinex, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Vaccinex, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Vaccinex, Inc..

Years

Calculation mode

= -$159M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$16M	-$16M	-$16M	-$16M	-$16M	-$16M	-$16M	-$16M	-$16M	-$16M	-$16M	-$159M
DCF		-$14M	-$13M	-$12M	-$11M	-$9.9M	-$9M	-$8.1M	-$7.4M	-$6.7M	-$6.1M	-$61M
Value	-$159M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2017	08/2018	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-21K%	-	-4K%	-6K%	-58K%	-2K%	-7K%	-4K%	-4K%
ROA	-	-	-124%	-692%	-242%	-227%	-248%	-558%	-383%
ROE	-	-	-192%	1K%	1K%	-302%	-382%	876%	-

Bad Net Margins (-3.93K%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2017	08/2018	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-0.04	-0.01	-0.01	-0.01	-0
Debt over Equity	-	-	-	-	-0.43	0.03	0.03	-0.04	-0.03
Growth Stability	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-0)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (-0.03)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2017	08/2018	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-28%	-90%	2K%	-69%	107%	9%
Earnings YoY growth	-	-	-	8%	-9%	-22%	-11%	2%	-
Equity YoY growth	-	-	-	-115%	15%	-384%	-30%	-145%	-6%
FCF YoY growth	-	-	-	21%	-6%	-12%	-24%	-10%	-